OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

Group 1: Appointment of Dr. Andreas Niethammer - OSR Holdings, Inc. has appointed Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, focusing on the development of orally administered T-cell activators, including VXM01, an anti-VEGFR-2 candidate in clinical stages [1][2] - Dr. Niethammer is an internationally recognized expert in oncology with over 20 years of experience in cancer immunotherapy and clinical development, having held leadership roles in several global biopharmaceutical companies [2][4] Group 2: Vaximm AG and its Focus - Vaximm AG, a wholly owned subsidiary of OSR Holdings, is a Swiss-German biotech company dedicated to developing oral T-cell immunotherapies for cancer, with its lead program VXM01 having completed Phase I/II clinical trials for pancreatic cancer and glioblastoma [5][6] - The company aims to activate targeted cytotoxic T-cell responses through oral administration, representing a novel approach in cancer treatment [5] Group 3: Future Directions and Vision - Dr. Niethammer expressed optimism about accelerating the development of oral immunotherapies with the potential to improve outcomes for patients with challenging cancers and other diseases with high unmet needs [4] - OSR Holdings envisions acquiring and operating a portfolio of innovative healthcare companies to enhance patient care through advanced research and development [6]